Hosted on MSN1mon
Eli Lilly to Acquire Scorpion Therapeutics' Breast Cancer Candidate For up to $2.5 BillionScorpion would spin out its non-phosphoinositide 3-kinase alpha pipeline assets into a new company that would be owned by Scorpion's existing shareholders, with Lilly retaining a minority interest.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback